Third Circuit under fire over FTC v AbbVie ruling

The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AbbVie says bar for ‘sham litigation’ is too low

3 June 2021 AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.

Americas

FTC’s $448m AbbVie win overturned

2 October 2020 A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.

Americas

AbbVie and Besins to pay FTC $448m in sham litigation case

2 July 2018 Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.

More features

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

Third Circuit under fire over FTC v AbbVie ruling

More on this story

Editor's picks

Editor's picks

More features